Astel­las fol­lows up $3B gene ther­a­py buy­out with $109M plan to ac­cel­er­ate a man­u­fac­tur­ing boom

Just weeks af­ter clos­ing on their $3 bil­lion Au­dentes buy­out, Astel­las is fol­low­ing up with a $109 mil­lion plan to build a new man­u­fac­tur­ing fa­cil­i­ty in or­der to be­come a play­er in the boom­ing gene ther­a­py field.

Astel­las is build­ing out a 135,000-square-foot plant from the ground up, with plans to add 200 jobs in San­ford, NC, a re­gion that has be­come home to a thriv­ing hub of drug-mak­ing op­er­a­tions. Like a num­ber of star­tups in the field, Au­dentes has been pur­su­ing AAV pro­grams fash­ioned with tech orig­i­nal­ly de­signed by Penn’s Jim Wil­son.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER